Hürthle cell carcinoma: current perspectives
Authors:
Open Access
- 1 November 2016
- journal article
- review article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 9, 6873-6884
Abstract
Hürthle cell carcinoma (HCC) can present either as a minimally invasive or as a widely invasive tumor. HCC generally has a more aggressive clinical behavior compared with the other differentiated thyroid cancers, and it is associated with a higher rate of distant metastases. Minimally invasive HCC demonstrates much less aggressive behavior; lesions 2 cm and those with nodal and distant metastases. Patients with localized iodine-resistant disease who are not candidates for a wait-and-watch approach can be treated with localized therapies. Systemic therapy is reserved for patients with progressive, widely metastatic HCC.Keywords
This publication has 67 references indexed in Scilit:
- Institution‐specific risk of papillary thyroid carcinoma in atypia/follicular lesion of undetermined significanceHead & Neck, 2015
- Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid CancerNew England Journal of Medicine, 2015
- Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next‐generation sequencing assayCancer, 2014
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trialThe Lancet, 2014
- Hurthle cell carcinomaCancer, 2012
- The Bethesda System for Reporting Thyroid CytopathologyThyroid®, 2009
- Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients.2006
- Intensity‐modulated radiation therapy in head and neck cancers: An updateHead & Neck, 2005
- Hürthle cell carcinoma: A 60-year experienceAnnals of Surgical Oncology, 2002
- Distant Metastases in Differentiated Thyroid Carcinoma: A Multivariate Analysis of Prognostic Variables*The Journal of Clinical Endocrinology & Metabolism, 1988